To investigate the possible mechanisms by which 225Ac‐lintuzumab may potentiate or re‐sensitize resistant AML lines to the venetoclax, we assessed the impact of the antibody radio‐conjugate on cellular levels of antiapoptotic proteins MCL‐1, BCL‐2, and BCL‐XL. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.